Clopixol depot oil solution for injection ampoules 200mg 1ml №10

Composition

1 ml of oil solution contains:
active substance: zuclopentixol decanoate 200 mg;
excipient: triglycerides

pharmachologic effect

Clopixol Depot - antipsychotic (neuroleptic), a derivative of thioxanthene.

Clopixol has a pronounced antipsychotic and specific inhibitory effect. Clopixol may also have a transient, dose-dependent sedative effect, the rapid development of which at the beginning of therapy (before the onset of antipsychotic action) is an advantage in the treatment of acute and sub-acute psychoses.

Tolerance to the nonspecific sedative effect of the drug comes quickly.

Due to the specific inhibitory effect of the drug is especially indicated for agitation, anxiety, hostility or aggressiveness.

The therapeutic effect of Clopixol Depot is significantly more prolonged compared to Clopixol. This allows you to confidently carry out continuous antipsychotic treatment with Clopixol Depot, which is especially important for patients who do not perform medical appointments.

Clopixol depot prevents the development of frequent relapses associated with the voluntary interruption of oral medication by patients.

Indications

- Acute and chronic schizophrenia and other psychotic disorders, especially with hallucinations, paranoid delusions and mental disorders.
- States of agitation, increased anxiety, hostility, aggressiveness.

Contraindications

- Acute alcohol intoxication.
- Acute intoxication with barbiturates.
- Acute toxicity with opioid analgesics.
- Coma.

Use during pregnancy and lactation

Clopixol not recommended for use during pregnancy and lactation (breastfeeding).

Special notes

Malignant neuroleptic syndrome (NNS) is a rare but possible complication with a fatal outcome when using neuroleptics. The main symptoms of ZNS are hyperthermia, muscle rigidity and impaired consciousness in combination with dysfunction of the autonomic nervous system (labile blood pressure, tachycardia, increased sweating). In addition to the immediate cessation of neuroleptic intake, the use of general supportive measures and symptomatic treatment is urgently needed.
With long-term therapy, especially in large doses, it is necessary to conduct careful monitoring, periodically assessing the condition of patients, in order to make a decision to reduce the maintenance dosage.
The effect of Klopiksola Depot on the ability to drive a car and other mechanisms is possible. Therefore, at the beginning of therapy, care must be taken untiluntil the patient's response to treatment is determined.

Dosage and administration

The drug is prescribed as a deep intramuscular injection into the upper outer quadrant of the gluteal region.

The dose and the interval between injections is determined individually depending on the patient's condition.

Clopixol depot (200 mg / ml) with maintenance treatment is administered in doses of 200-400 mg (1-2 ml) every 2-4 weeks. In some cases, higher doses or shorter intervals between injections may be required.

- Transition from Clopixol for oral administration to intramuscular administration of Clopixol depot Daily dose (mg) Clopixol for oral administration x 8 = dose (mg) Clopixol depot for intramuscular administration once a week. Intake of Clopixol inside should be continued within the first week after the first injection, but in the reduced dose.

- Transition from intramuscular administration of Klopixol-Akufaz to intramuscular administration of Clopixol Depot Simultaneously with the final injection of Klopiksol-Akufaz (100 mg), 200-400 mg (1-2 ml) of Clopixol Depot (200 mg / ml) should be administered. Repeated injections of Klopixol Depot are performed every 2 weeks. If necessary, the use of the drug in higher doses or reducing the interval between injections is acceptable. Klopiksol-Akufaz and Clopixol Depot can be mixed in one syringe and administered as one combined injection. Subsequent doses of Clopixol Depot and the intervals between injections should be set depending on the patient's condition.

Side effects

Extrapyramidal disorders, tardive dyskinesia, neuroleptic malignant syndrome, drowsiness, dizziness, dry mouth, accommodation disturbance, urinary retention, constipation, tachycardia, orthostatic hypotension, changes in liver tests are possible.

Drug interaction

With simultaneous use of Clopixol may increase the sedative effect of ethanol, barbiturates and other means that have a inhibitory effect on the central nervous system.

Clopixol should not be used simultaneously with guanethidine and agents with a similar effect (since antipsychotics can block their hypotensive action).

With simultaneous use of Clopixol may reduce the effectiveness of levodopa and other adrenergic agents.

With simultaneous use of Clopixol with Metoclopramide and piperazine increases the risk of extrapyramidal symptoms.

Pharmaceutical incompatibility has not been established.

Overdosage

Symptoms: drowsiness, coma, extrapyramidal disorders, convulsions, hypotension, shock, hyper- or hypothermia are possible.
Treatment: in case of taking the drug inside it is necessary to wash the stomach as soon as possible, the use of a sorbent is recommended. In the future, conduct symptomatic and supportive therapy. Measures should be taken to support the activity of the respiratory and cardiovascular systems. Do not use adrenaline.

Storage conditions

Store in a dark place at a temperature not exceeding 25 ° C.